206 related articles for article (PubMed ID: 35179483)
1. Cannabidiol activates neuronal Kv7 channels.
Zhang HB; Heckman L; Niday Z; Jo S; Fujita A; Shim J; Pandey R; Al Jandal H; Jayakar S; Barrett LB; Smith J; Woolf CJ; Bean BP
Elife; 2022 Feb; 11():. PubMed ID: 35179483
[TBL] [Abstract][Full Text] [Related]
2. Role of Kv7.2/Kv7.3 and M
Kreir M; De Bondt A; Van den Wyngaert I; Teuns G; Lu HR; Gallacher DJ
Eur J Pharmacol; 2019 Sep; 858():172474. PubMed ID: 31238068
[TBL] [Abstract][Full Text] [Related]
3. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.
Zhang F; Liu Y; Tang F; Liang B; Chen H; Zhang H; Wang K
FASEB J; 2019 Aug; 33(8):9154-9166. PubMed ID: 31063701
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II regulates neuronal excitability via phosphatidylinositol 4,5-bisphosphate-dependent modulation of Kv7 (M-type) K+ channels.
Zaika O; Lara LS; Gamper N; Hilgemann DW; Jaffe DB; Shapiro MS
J Physiol; 2006 Aug; 575(Pt 1):49-67. PubMed ID: 16777936
[TBL] [Abstract][Full Text] [Related]
5. A conserved threonine in the S1-S2 loop of KV7.2 and K V7.3 channels regulates voltage-dependent activation.
Füll Y; Seebohm G; Lerche H; Maljevic S
Pflugers Arch; 2013 Jun; 465(6):797-804. PubMed ID: 23271449
[TBL] [Abstract][Full Text] [Related]
6. Modulation of K(v)7 potassium channels by a novel opener pyrazolo[1,5-a]pyrimidin-7(4H)-one compound QO-58.
Zhang F; Mi Y; Qi JL; Li JW; Si M; Guan BC; Du XN; An HL; Zhang HL
Br J Pharmacol; 2013 Feb; 168(4):1030-42. PubMed ID: 23013484
[TBL] [Abstract][Full Text] [Related]
7. Distinct subunit contributions to the activation of M-type potassium channels by PI(4,5)P2.
Telezhkin V; Brown DA; Gibb AJ
J Gen Physiol; 2012 Jul; 140(1):41-53. PubMed ID: 22689829
[TBL] [Abstract][Full Text] [Related]
8. Activation of KCNQ2/3 potassium channels by novel pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives.
Jia C; Qi J; Zhang F; Mi Y; Zhang X; Chen X; Liu L; Du X; Zhang H
Pharmacology; 2011; 87(5-6):297-310. PubMed ID: 21577044
[TBL] [Abstract][Full Text] [Related]
9. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
Wickenden AD; Krajewski JL; London B; Wagoner PK; Wilson WA; Clark S; Roeloffs R; McNaughton-Smith G; Rigdon GC
Mol Pharmacol; 2008 Mar; 73(3):977-86. PubMed ID: 18089837
[TBL] [Abstract][Full Text] [Related]
10. Structural requirements of membrane phospholipids for M-type potassium channel activation and binding.
Telezhkin V; Reilly JM; Thomas AM; Tinker A; Brown DA
J Biol Chem; 2012 Mar; 287(13):10001-10012. PubMed ID: 22303005
[TBL] [Abstract][Full Text] [Related]
11. Suppression of KV7/KCNQ potassium channel enhances neuronal differentiation of PC12 cells.
Zhou N; Huang S; Li L; Huang D; Yan Y; Du X; Zhang H
Neuroscience; 2016 Oct; 333():356-67. PubMed ID: 27450567
[TBL] [Abstract][Full Text] [Related]
12. Early-onset epileptic encephalopathy caused by gain-of-function mutations in the voltage sensor of Kv7.2 and Kv7.3 potassium channel subunits.
Miceli F; Soldovieri MV; Ambrosino P; De Maria M; Migliore M; Migliore R; Taglialatela M
J Neurosci; 2015 Mar; 35(9):3782-93. PubMed ID: 25740509
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
Zhou P; Yu H; Gu M; Nan FJ; Gao Z; Li M
Proc Natl Acad Sci U S A; 2013 May; 110(21):8726-31. PubMed ID: 23650395
[TBL] [Abstract][Full Text] [Related]
14. Made for "anchorin": Kv7.2/7.3 (KCNQ2/KCNQ3) channels and the modulation of neuronal excitability in vertebrate axons.
Cooper EC
Semin Cell Dev Biol; 2011 Apr; 22(2):185-92. PubMed ID: 20940059
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites.
Miceli F; Soldovieri MV; Ambrosino P; Manocchio L; Mosca I; Taglialatela M
Curr Med Chem; 2018; 25(23):2637-2660. PubMed ID: 29022505
[TBL] [Abstract][Full Text] [Related]
16. Functional and behavioral signatures of Kv7 activator drug subtypes.
Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
[TBL] [Abstract][Full Text] [Related]
17. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
Padilla K; Wickenden AD; Gerlach AC; McCormack K
Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
[TBL] [Abstract][Full Text] [Related]
18. Heteromeric Assembly of Truncated Neuronal Kv7 Channels: Implications for Neurologic Disease and Pharmacotherapy.
Li J; Maghera J; Lamothe SM; Marco EJ; Kurata HT
Mol Pharmacol; 2020 Sep; 98(3):192-202. PubMed ID: 32580997
[TBL] [Abstract][Full Text] [Related]
19. A possible link between KCNQ2- and STXBP1-related encephalopathies: STXBP1 reduces the inhibitory impact of syntaxin-1A on M current.
Devaux J; Dhifallah S; De Maria M; Stuart-Lopez G; Becq H; Milh M; Molinari F; Aniksztejn L
Epilepsia; 2017 Dec; 58(12):2073-2084. PubMed ID: 29067685
[TBL] [Abstract][Full Text] [Related]
20. Identification of potassium channel proteins Kv7.2/7.3 as common partners of the dopamine and glutamate transporters DAT and GLT-1.
Bartolomé-Martín D; Ibáñez I; Piniella D; Martínez-Blanco E; Pelaz SG; Zafra F
Neuropharmacology; 2019 Dec; 161():107568. PubMed ID: 30885609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
